Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2008; 29(01): 59-61
DOI: 10.4103/0971-5851.51443
Review Article

Current Strategies in the Management of Pediatric Hodgkin’s Lymphoma

Veronique Dinand
Department of Pediatric Hematology Oncology, Sir Ganga Ram Hospital, Rajender Nagar, New Delhi-110 060, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
07 March 2022

© 2008. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Glaser SL, Hsu JL. Hodgkin′s disease in Asians: incidence patterns and risk factors in populationbased data. Leuk Res 2002;26(3):261-269.
  • 2 Dinand V, Arya LS. Epidemiology of childhood Hodgkin′s disease: is it different in developing countries? Indian Pediatr 2006;43(2):141-147.
  • 3 Yeole BB, Advani SH, Sunny L. Epidemiological features of childhood cancers in greater Mumbai. Indian Pediatr 2001;38(11):1270-1277.
  • 4 Tyagi BB, Manoharan N, Raina V. Childhood Cancer Incidence in Delhi, 1996 - 2000. Indian J Med Paed Oncol 2006;27(4):13-18.
  • 5 Nandakumar A, Anantha N, Appaji L, et al. Descriptive epidemiology of childhood cancers in Bangalore, India. Cancer Causes Control 1996;7(4):405- 410.
  • 6 Schwartz CL. Special issues in pediatric Hodgkin′s disease. Eur J Haematol 2005;75(suppl. 66):55-62.
  • 7 Mueller N, Evans A, Harris NL, et al. Hodgkin′s disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med 1989;320(11):689-695.
  • 8 Hjalgrim H, Askling J, Rostgaard K, et al. Characteristics of Hodgkin′s lymphoma after infectious mononucleosis. N Engl J Med 2003;349(14):1324-1332.
  • 9 Dinand V, Dawar R, Arya LS, et al. Hodgkin′s lymphoma in Indian children: prevalence and significance of Epstein-Barr virus detection in Hodgkin′s and Reed Sternberg cells. Eur J Cancer 2007;43:161-168.
  • 10 Caldwell RG, Wilson JB, Anderson SJ, Longnecker R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 1998;9(3):405-411.
  • 11 Lam N, Sugden B. CD40 and its viral mimic, LMP1: similar means to different ends. Cell signal 2003;15(1):9-16.
  • 12 Jarrett RF. Viruses and Hodgkin′s lymphoma. Ann Oncol 2002;13 Suppl 1:23-29.
  • 13 Garbuglia AR, Iezzi T, Capobianchi MR, et al. Detection of TT virus in lymph node biopsies of Bcell lymphoma and Hodgkin′s disease, and its association with EBV infection. Int J Immunopathol Pharmacol 2003;16(2):109-118.
  • 14 Ferraris AM, Rancchi O, Rapezzi D, et al. Familial Hodgkin′s disease: A disease of young adulthood? Ann Hematol 1997;74:131-134.
  • 15 Alexander FE, Jarrett RF, Cartwright RA, et al. Epstein-Barr Virus and HLA-DPB1-FNx010301 in young adult Hodgkin′s disease: evidence for inherited susceptibility to Epstein-Barr Virus in cases that are EBV(+ve). Cancer Epidemiol Biomarkers Prev 2001;10(6):705-709.
  • 16 Landgren O, Engels EA, Pfeiffer RM, et al. Autoimmunity and Susceptibility to Hodgkin Lymphoma: A Population-Based Case-Control Study in Scandinavia. J Natl Cancer Inst 2006;98(18):1321- 1330.
  • 17 Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting -Airlie House, Virginia, November, 1997. J Clin Oncol 1999;17(12):3835-3849.
  • 18 Nogova L, Rudiger T, Engert A. Biology, clinical course and management of nodular lymphocytepredominant Hodgkin lymphoma . Hematology Am Soc Hematol Educ Program 2006:266-272.
  • 19 Kόppers R, Rajewsky K, Zhao M, et al. Hodgkin′s disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA 1994;91:10962- 10966.
  • 20 Seitz V, Hummel M, Anagnostopoulos I, Stein H. Analysis of BCL-6 mutations in classic Hodgkin disease of the B- and T-cell type. Blood 2001;97(8):2401- 1405.
  • 21 Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin′s disease: Cotswolds Meeting. J Clin Oncol 1989;7:1630-1636.
  • 22 Cheson BD, Pfistner B, Juweid ME, et al. Revised Response Criteria for Malignant Lymphoma. J Clin Oncol 2007;25(5):579-586.
  • 23 Tatsumi M, Miller JH, Wahl RL. 18F-FDG PET/CT in evaluating non-CNS pediatric malignancies. J Nucl Med 2007;48(12):1923-1931.
  • 24 Juweid ME. Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin′s lymphoma. Hematology 2006:259-265.
  • 25 Kabickova E, Sumerauer D, Cumlivska E, et al. Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin′s disease. Euro J Nucl Med Mol Imaging 2006;33(9):1025-1031.
  • 26 Schellong G, Pφtter R, Brδmswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin′s disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin′s Disease Study Group. J Clin Oncol 1999;17(12):3736-3744.
  • 27 Landman-Parker J, Pacquement H, Leblanc T, et al. Localized childhood Hodgkin′s disease: responseadapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisolone before low-dose radiation therapy - Results of the French Society of Pediatric Oncology study MDH90. J Clin Oncol 2000;18:1500-1507.
  • 28 Smith RS, Chen Q, Hudson MM, et al. Prognostic factors for children with Hodgkin′s disease treated with combined-modality therapy. J Clin Oncol 2003;21(10):2026-2033.
  • 29 Jarrett RF, Stark GL, White J, et al. Scotland and Newcastle Epidemiology of Hodgkin′s Disease Study Group. Impact of tumour Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin′s lymphoma: a population-based study. Blood 2005;106(7):2444-2451.
  • 30 Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended followup of childhood Hodgkin′s disease: report from the Late Effects Study Group. J Clin Oncol 2003;21(23):4386-4394.
  • 31 Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin′s disease who achieve a complete response to chemotherapy. J Clin Oncol 2002;20(18):3765-3771.
  • 32 Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin′s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004;22(1):62-68.
  • 33 Kung FH, Schwartz CL, Ferree CR, et al. POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children′s Oncology Group. J Pediatr Hematol Oncol 2006;28(6):362-368.
  • 34 Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgki lymphoma. Blood 2006;107:52-59.
  • 35 Diehl V, Kobe C, Haverkamp H, et al. FDG-PET for assessment of residual tissue after completion of chemotherapy in Hodgkin lymphoma - Report on the 2nd interim analysis of the PET investigation in the trial HD15 of the GHSG. Blood 2007;110(11)70a (Abstract# 212).
  • 36 Donaldson SS, Link MP, Weinstein HJ, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin′s disease. J Clin Oncol 2007;25(3):332-337.
  • 37 Tebbi CK, Mendenhall N, London WB, et al; Children′s Oncology Group. Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study. Pediatr Blood Cancer 2006;46(2):198-202.
  • 38 Krasin MJ, Rai SN, Kun LE. Patterns of treatment failure in pediatric and young adult patients with Hodgkin′s disease: local disease control with combined-modality therapy. J Clin Oncol 2005;23(33):8406-8413.
  • 39 Kelly KM, Hutchinson RJ, Sposto R, et al. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin′s lymphoma: preliminary results from the Children′s Cancer Group Study CCG-59704. Ann Oncol 2002;13(suppl 1):107-111.
  • 40 Cairo MS, Shen V, Krailo MD, et al. Prospective randomised trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin and etoposide in children with recurrent or refractory solid tumours: a Children′s Cancer Group report. J Pediatr Hematol Oncol 2001;23(1):30- 38.
  • 41 Kobrinsky NL, Sposto R, Shah NR, et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin′s lymphoma and Hodgkin′s disease with dexamethasone, etoposide, cisplatin, cytarabin and L-asparaginase, maintenance therapy and transplantation: Children′s Cancer Group Study CCG-5912. J Clin Oncol 2001;19(9):2390-2396.
  • 42 Ozkaynak MF, Jayabose S. Gemcitabine and vinorelbine as a salvage regimen for relapse in Hodgkin′s lymphoma after autologous hematopoietic stem cell transplantation. Pediatr Hematol Oncol 2004;21(2):107-113.
  • 43 Schellong G, Dφrffel W, Claviez A, et al. Salvage therapy of progressive and recurrent Hodgkin′s disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 2005;23(25):6181-6189.
  • 44 Lieskovsky YE, Donaldson SS, Torres MA, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin′s disease: results and prognostic indices. J Clin Oncol 2004;22(22):4532-4540.
  • 45 Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al. Lymphocyte-predominant Hodgkin′s lymphoma in children: therapeutic abstention after initial lymph node resection-a Study of the French Society of Pediatric Oncology. J Clin Oncol 2003;21(15):2948- 2952.
  • 46 Mauz-Kφrholz C, Gorde-Grosjean S, Hasenclever D, et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphomaexperience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007;110(1):179- 185.
  • 47 Murphy SB, Morgan ER, Katzenstein HM, Kletzel M. Results of little or no treatment for lymphocytepredominant Hodgkin disease in children and adolescents. J Ped Hematol Oncol 2003;25(9):684-687.
  • 48 Wedgwood AR, Fanale MA, Fayad LE, et al. Rituximab + ABVD improves event-free survival in patients with classical Hodgkin′s lymphoma in all International Prognostic Score (IPS) groups and in patients who have PET positive disease after 2-3 cycles of therapy. Blood 2007;110(11)71a (Abstract# 215).
  • 49 Kennedy-Nasser AA, Bollard CM, Rooney CM. Adoptive immunotherapy for Hodgkin′s lymphoma. Int J Hematol 2006;83(5):385-390.
  • 50 Hudson MM, Donaldson SS. Hodgkin′s disease. In: Pizzo PA and Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia; Lippincott Williams& Wilkins; 2002; p. 644.